Literature DB >> 23812941

Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells.

Ion Cristóbal, Cristina Cirauqui, Remedios Castello-Cros, Laura Garcia-Orti, María J Calasanz, María D Odero.   

Abstract

Entities:  

Keywords:  AKT; AML; PP2A; PPP2R5E

Mesh：

Substances：

Year:  2013        PMID： 23812941      PMCID： PMC3762109          DOI： 10.3324/haematol.2013.084731

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity.

Authors:  Géraldine Rocher; Claire Letourneux; Philippe Lenormand; Françoise Porteu
Journal:  J Biol Chem       Date:  2007-01-02       Impact factor: 5.157

Review 2.  Protein phosphatase 2A: a target for anticancer therapy.

Authors:  Danilo Perrotti; Paolo Neviani
Journal:  Lancet Oncol       Date:  2013-05       Impact factor: 41.316

3.  The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.

Authors:  Yingzi Wang; Andrei V Krivtsov; Amit U Sinha; Trista E North; Wolfram Goessling; Zhaohui Feng; Leonard I Zon; Scott A Armstrong
Journal:  Science       Date:  2010-03-26       Impact factor: 47.728

4.  PP2A T61 epsilon is an inhibitor of MAP4K3 in nutrient signaling to mTOR.

Authors:  Lijun Yan; Virginie Mieulet; Darren Burgess; Greg M Findlay; Katherine Sully; Julia Procter; Jozef Goris; Veerle Janssens; Nick A Morrice; Richard F Lamb
Journal:  Mol Cell       Date:  2010-03-12       Impact factor: 17.970

5.  Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia.

Authors:  Konstantinos J Mavrakis; Andrew L Wolfe; Elisa Oricchio; Teresa Palomero; Kim de Keersmaecker; Katherine McJunkin; Johannes Zuber; Taneisha James; Aly A Khan; Christina S Leslie; Joel S Parker; Patrick J Paddison; Wayne Tam; Adolfo Ferrando; Hans-Guido Wendel
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

6.  Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers.

Authors:  Kathryn G Roberts; Amanda M Smith; Fiona McDougall; Helen Carpenter; Martin Horan; Paolo Neviani; Jason A Powell; Daniel Thomas; Mark A Guthridge; Danilo Perrotti; Alistair T R Sim; Leonie K Ashman; Nicole M Verrills
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  PP2A:B56epsilon is required for eye induction and eye field separation.

Authors:  Anna M Rorick; Wenyan Mei; Nicole L Liette; Christopher Phiel; Heithem M El-Hodiri; Jing Yang
Journal:  Dev Biol       Date:  2006-10-10       Impact factor: 3.582

Review 9.  Multiple pathways regulated by the tumor suppressor PP2A in transformation.

Authors:  Jukka Westermarck; William C Hahn
Journal:  Trends Mol Med       Date:  2008-03-10       Impact factor: 11.951

10.  PP2A:B56epsilon is required for Wnt/beta-catenin signaling during embryonic development.

Authors:  Jing Yang; Jinling Wu; Change Tan; Peter S Klein
Journal:  Development       Date:  2003-10-01       Impact factor: 6.868
View more
  13 in total

1.  Kelch-like protein 42 is a profibrotic ubiquitin E3 ligase involved in systemic sclerosis.

Authors:  Travis B Lear; Karina C Lockwood; Mads Larsen; Ferhan Tuncer; Jason R Kennerdell; Christina Morse; Eleanor Valenzi; Tracy Tabib; Michael J Jurczak; Daniel J Kass; John W Evankovich; Toren Finkel; Robert Lafyatis; Yuan Liu; Bill B Chen
Journal:  J Biol Chem       Date:  2020-02-17       Impact factor: 5.157

2.  Loss of protein phosphatase 2A regulatory subunit B56δ promotes spontaneous tumorigenesis in vivo.

Authors:  C Lambrecht; L Libbrecht; X Sagaert; P Pauwels; Y Hoorne; J Crowther; J V Louis; W Sents; A Sablina; V Janssens
Journal:  Oncogene       Date:  2017-10-02       Impact factor: 9.867

Review 3.  The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: Challenges and opportunities.

Authors:  Nithya Mudgapalli; Palanisamy Nallasamy; Haritha Chava; Srinivas Chava; Anup S Pathania; Venugopal Gunda; Santhi Gorantla; Manoj K Pandey; Subash C Gupta; Kishore B Challagundla
Journal:  Mol Aspects Med       Date:  2019-10-14

4.  Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns.

Authors:  Ingrid Cifola; Marta Lionetti; Eva Pinatel; Katia Todoerti; Eleonora Mangano; Alessandro Pietrelli; Sonia Fabris; Laura Mosca; Vittorio Simeon; Maria Teresa Petrucci; Fortunato Morabito; Massimo Offidani; Francesco Di Raimondo; Antonietta Falcone; Tommaso Caravita; Cristina Battaglia; Gianluca De Bellis; Antonio Palumbo; Pellegrino Musto; Antonino Neri
Journal:  Oncotarget       Date:  2015-07-10

Review 5.  The Interplay between PP2A and microRNAs in Leukemia.

Authors:  Peter P Ruvolo
Journal:  Front Oncol       Date:  2015-02-20       Impact factor: 6.244

Review 6.  The Basic Biology of PP2A in Hematologic Cells and Malignancies.

Authors:  Dorien Haesen; Ward Sents; Katleen Lemaire; Yana Hoorne; Veerle Janssens
Journal:  Front Oncol       Date:  2014-12-11       Impact factor: 6.244

7.  Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.

Authors:  Geoffrey Shouse; Rosalia de Necochea-Campion; Saied Mirshahidi; Xuan Liu; Chien-Shing Chen
Journal:  Oncotarget       Date:  2016-09-20

8.  LINC00857 expression predicts and mediates the response to platinum-based chemotherapy in muscle-invasive bladder cancer.

Authors:  Aleksandra M Dudek; Jasmijn G M van Kampen; J Alfred Witjes; Lambertus A L M Kiemeney; Gerald W Verhaegh
Journal:  Cancer Med       Date:  2018-06-01       Impact factor: 4.452

Review 9.  Protein phosphatase 2A - structure, function and role in neurodevelopmental disorders.

Authors:  Priyanka Sandal; Chian Ju Jong; Ronald A Merrill; Jianing Song; Stefan Strack
Journal:  J Cell Sci       Date:  2021-07-06       Impact factor: 5.235

Review 10.  Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia.

Authors:  Elena Arriazu; Raffaella Pippa; María D Odero
Journal:  Front Oncol       Date:  2016-04-06       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.